Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), H. Iwamoto (Hiroshima, Japan), H. Tanahashi (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), L. Carlson (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), N. Hattori (Hiroshima, Japan), M. Skold (Stockhlom, Sweden). Elevated leukocyte count predicts survival in patients with idiopathic pulmonary fibrosis: analysis from the Swedish and Japanese cohorts. 393

Member's Comments

No comment yet.

Related content which might interest you: Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry Source: Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019 Year: 2020 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Prognostic factors affecting survival of idiopathic pulmonary fibrosis in Korean population Source: Eur Respir J 2007; 30: Suppl. 51, 578s Year: 2007 Effect of MUC5B gene polymorphism on survival in a Lebanese population of patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018 Year: 2019 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Low income and progression free survival in idiopathic pulmonary fibrosis: an association to  uncover Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis? Year: 2020 KL-6 compared to LDH as a prognostic factor in Caucasian patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Prognostic evaluation in Chinese patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020